Brown Advisory Inc. Sells 104,378 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Brown Advisory Inc. trimmed its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,641,753 shares of the medical equipment provider's stock after selling 104,378 shares during the period. Intuitive Surgical comprises 1.2% of Brown Advisory Inc.'s investment portfolio, making the stock its 18th biggest position. Brown Advisory Inc. owned approximately 0.46% of Intuitive Surgical worth $813,112,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Intuitive Surgical in the fourth quarter valued at about $2,401,493,000. GAMMA Investing LLC raised its holdings in shares of Intuitive Surgical by 54,010.7% in the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock worth $14,999,630,000 after purchasing an additional 3,022,979 shares during the period. Capital Research Global Investors raised its holdings in shares of Intuitive Surgical by 25.5% in the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider's stock worth $1,764,904,000 after purchasing an additional 687,906 shares during the period. Northern Trust Corp lifted its stake in Intuitive Surgical by 15.8% in the fourth quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock valued at $1,889,126,000 after purchasing an additional 494,496 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after purchasing an additional 360,591 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Jami K. Nachtsheim sold 2,400 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the transaction, the director directly owned 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Desantis sold 188 shares of the company's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the completion of the sale, the executive vice president directly owned 5,224 shares of the company's stock, valued at $2,695,113.84. This trade represents a 3.47% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 4,998 shares of company stock worth $2,611,577. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft lowered Intuitive Surgical from a "hold" rating to a "sell" rating and lowered their target price for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Royal Bank Of Canada dropped their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the stock a "buy" rating in a research report on Monday, April 14th. Barclays reduced their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Finally, Citigroup restated a "buy" rating and set a $650.00 price target (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $592.59.

Intuitive Surgical Stock Performance

ISRG traded down $13.99 on Friday, reaching $512.06. The company had a trading volume of 2,951,229 shares, compared to its average volume of 1,679,961. Intuitive Surgical, Inc. has a 52-week low of $413.82 and a 52-week high of $616.00. The company has a market cap of $183.53 billion, a price-to-earnings ratio of 75.08, a P/E/G ratio of 5.58 and a beta of 1.64. The business has a 50 day simple moving average of $537.85 and a 200 day simple moving average of $536.69.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The firm had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter last year, the company posted $1.50 EPS. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.